Apollo Hospitals Enterprise Limited share price

NSE: APOLLOHOSP · BSE: 508869 · ISIN INE437A01024

Key numbers

Market cap
₹ 1,27,810 Cr
Current price
₹ 8,889.00
52-week high / low
₹ 9,071 / 6,697
Stock P/E
61.4
Book value
₹ 659.3
Dividend yield
0.22%
ROCE
19.1%
ROE
21.9%
Debt to equity
0.90
Sales growth (3 yrs)
14.8%
Profit growth (3 yrs)
33.3%
1-year return
16.3%

About Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India. It operates through Healthcare Services, Retail Health & Diagnostics, Digital Health & Pharmacy Distribution, and Others segments. The company's healthcare facilities comprise primary, secondary, and tertiary care, as well as specialty facilities. It offers services in cardiac sciences, oncology, neurosciences, gastroenterology, orthopedics, urology, organ transplantation, pulmonology, obstetrics and gynecology, internal medicine, vascular surgery, pediatrics, cosmetology, emergency medicine, bariatric surgery, general surgery, colorectal surgery, dentistry, nephrology, dermatology, endocrinology, preventive medicine, interventional radiology, ophthalmology, and integrative medicine, as well as robotic surgery and genomics. The company also provides project consultancy, medical educational institutes, Medvarsity for e-learning, and research services, as well as acts as an agent for life, general, and health insurance. In addition, it operates hospitals, pharmacies, primary care clinics, and diagnostic centers; short stay facilities, boutique birthing centers, multi-specialty…

Quarterly results

Consolidated figures in ₹ crores

Mar 2025Jun 2025Dec 2025Mar 2026Jun 2026
Sales5,5925,8426,4776,6067,044
Operating profit7708529651,0111,092
Net profit390433502529581
EPS (₹)21.1030.1034.9436.8240.39

Investor presentation summary (2026-08-12)

AI summary of the presentation · tone: Positive · source document

Key numbers

  • Raysorel . TrichyrT—®Ranipet: 1 -4 |‘/|~}' % 186,630 Avg Revenue per EBITDA 8,617 Mio 1 20%
  • 375 mio. EBITDA margin of established units at 25.9% in

Guidance & outlook

  • o PATincreased 78% to Rs. 1,017 Mn in Q1°FY 27, compared to Rs. 571 Mnin Q1'FY26.
  • o Platform GMV (23% YoY Growth) : Rs 5,351 Mn in Q1" FY27, over Rs. 4,364 Mn Q1' FY26

Growth & demand

  • e « Platform GMV: INR 535 Cr. in Q1FY27, growth
  • HealthCo o Al-led Consultations & Insurance Growth: Al-driven patient triaging scaled, while insurance grew ~6x.

Margins & costs

  • & Karur: 1 0 IP Patient " 8% Overseas (Managed) " : Margin qw
  • EBITDA (Pre 24|7 Cost) 8,617 590 2,624 11,831

Capex & expansion

  • Ahmedabad: 3 N iCapacity beds include only census capacity beds and doesn't include emergency, daycare beds, recovery room, dialysis, endoscopy etc.
  • o Efficient User Acquisition: User growth remained strong despite lower marketing spend, led by omni-channel and non-metro expansion.

Peers in Medical Care Facilities

Data for information only, not investment advice. Prices end of day.